Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Schellekens

Showing results (161-170 of 242) with videos related to

Pageof 25
Sort By:
Infection|September 4, 2012
Real-time PCR to distinguish livestock-associated (ST398) from non-livestock-associated (methicillin-resistant) Staphylococcus aureusM L J G M van Meurs, J J A Schellekens, A J de Neeling, et al.
Journal of Intellectual & Developmental Disability|January 17, 2025
Development of a personalised substance use disorder treatment for people with mild intellectual disabilities or borderline intellectual functioning: An intervention mapping approachLotte C F Gosens, Roy Otten, Jannet M de Jonge, et al.
The Lancet. Infectious Diseases|September 8, 2016
Rethinking the risk-benefit ratio of efavirenz in HIV-infected childrenLisa Van de Wijer, Arnt F A Schellekens, David M Burger, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 21, 2015
Citrulline is an Essential Constituent of Antigenic Determinants Recognized by Rheumatoid Arthritis-specific Autoantibodies. 1998Gerard A Schellekens, Ben A W de Jong, Frank H J van den Hoogen, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 1, 2017
Safety Evaluation of Efavirenz in Children: Don't Forget the Central Nervous SystemLisa Van de Wijer, Grace D Kinabo, Deborah N Mchaile, et al.
Journal of Mental Health Research in Intellectual Disabilities|April 9, 2025
Experiences with Take it Personal!+ from People with Mild Intellectual Disability or Borderline Intellectual Functioning and Substance Use Disorder and Their Confidants: A Qualitative StudyLotte C F Gosens, Robert Didden, Jannet M de Jonge, et al.
Epilepsia|March 7, 2002
Randomized double-blind parallel-group study comparing cognitive effects of a low-dose lamotrigine with valproate and placebo in healthy volunteersA P Aldenkamp, J Arends, H P R Bootsma, et al.
Arthritis and Rheumatism|January 22, 2000
The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptideG A Schellekens, H Visser, B A de Jong, et al.
Analytica Chimica Acta|October 15, 2025
Evaluation of the relationship between peak characteristics and detection performance in two-dimensional chromatographic dataNino B L Milani, Nard C A Schellekens, Alan R Garcia Cicourel, et al.
Clinical Pharmacokinetics|May 25, 2025
Optimizing Nortriptyline Dosing: A Comparison between Pharmacogenetics-Based, Phenotype-Based, and Standard DosingCornelis F Vos, Marieke J H Coenen, Sophie E Ter Hark, et al.
Pageof 25

Showing results (161-170 of 242) with videos related to

Sort By:
Pageof 25
Infection|September 4, 2012
Real-time PCR to distinguish livestock-associated (ST398) from non-livestock-associated (methicillin-resistant) Staphylococcus aureusM L J G M van Meurs, J J A Schellekens, A J de Neeling, et al.
Journal of Intellectual & Developmental Disability|January 17, 2025
Development of a personalised substance use disorder treatment for people with mild intellectual disabilities or borderline intellectual functioning: An intervention mapping approachLotte C F Gosens, Roy Otten, Jannet M de Jonge, et al.
The Lancet. Infectious Diseases|September 8, 2016
Rethinking the risk-benefit ratio of efavirenz in HIV-infected childrenLisa Van de Wijer, Arnt F A Schellekens, David M Burger, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 21, 2015
Citrulline is an Essential Constituent of Antigenic Determinants Recognized by Rheumatoid Arthritis-specific Autoantibodies. 1998Gerard A Schellekens, Ben A W de Jong, Frank H J van den Hoogen, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 1, 2017
Safety Evaluation of Efavirenz in Children: Don't Forget the Central Nervous SystemLisa Van de Wijer, Grace D Kinabo, Deborah N Mchaile, et al.
Journal of Mental Health Research in Intellectual Disabilities|April 9, 2025
Experiences with Take it Personal!+ from People with Mild Intellectual Disability or Borderline Intellectual Functioning and Substance Use Disorder and Their Confidants: A Qualitative StudyLotte C F Gosens, Robert Didden, Jannet M de Jonge, et al.
Epilepsia|March 7, 2002
Randomized double-blind parallel-group study comparing cognitive effects of a low-dose lamotrigine with valproate and placebo in healthy volunteersA P Aldenkamp, J Arends, H P R Bootsma, et al.
Arthritis and Rheumatism|January 22, 2000
The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptideG A Schellekens, H Visser, B A de Jong, et al.
Analytica Chimica Acta|October 15, 2025
Evaluation of the relationship between peak characteristics and detection performance in two-dimensional chromatographic dataNino B L Milani, Nard C A Schellekens, Alan R Garcia Cicourel, et al.
Clinical Pharmacokinetics|May 25, 2025
Optimizing Nortriptyline Dosing: A Comparison between Pharmacogenetics-Based, Phenotype-Based, and Standard DosingCornelis F Vos, Marieke J H Coenen, Sophie E Ter Hark, et al.
Pageof 25